Related Experiment Video
Updated: Jun 3, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Advances in management of dermatofibrosarcoma protuberans
Hillary Johnson-Jahangir1, Désirée Ratner
1Department of Dermatology, Columbia University Medical Center, 161 Fort Washington Avenue, 12th Floor, New York, NY 10032, USA. hillary.johnson@gmail.com
Dermatologic Clinics
|March 23, 2011
Summary
Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. Surgical removal is key, but new targeted therapies like imatinib mesylate offer effective adjuvant treatment options for difficult cases.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Dermatofibrosarcoma protuberans (DFSP) is a rare soft-tissue neoplasm.
- DFSP typically affects the trunk and extremities in adults.
- While having low metastatic potential, DFSP poses a high risk of local recurrence due to subclinical spread.
Purpose of the Study:
- To review the treatment landscape for Dermatofibrosarcoma protuberans.
- To highlight the role of surgical excision and adjuvant therapies.
- To discuss the integration of targeted molecular therapies in DFSP management.
Main Methods:
- Review of current literature on DFSP treatment.
- Analysis of surgical techniques including Mohs micrographic surgery and wide local excision.
- Evaluation of adjuvant therapies such as radiation and targeted molecular agents.
Main Results:
- Surgical excision with clear margins is the primary treatment for DFSP.
- Adjuvant radiation therapy can reduce local recurrence when residual disease is present.
- Targeted therapies, including imatinib mesylate, show promise as effective adjuvant options.
Conclusions:
- Effective management of DFSP relies on complete surgical resection.
- Adjuvant therapies are crucial for managing unresectable, recurrent, or metastatic DFSP.
- Targeted molecular therapies represent a significant advancement in DFSP adjuvant treatment.
